No Data
No Data
A Quick Look at Today's Ratings for Ovid Therapeutics(OVID.US), With a Forecast Between $2 to $3
On Jun 19, major Wall Street analysts update their ratings for $Ovid Therapeutics(OVID.US)$, with price targets ranging from $2 to $3.TD Cowen analyst Ritu Baral maintains with a buy rating.Oppenheime
Ovid Therapeutics Price Target Cut to $5.00/Share From $11.00 by BTIG
Ovid Therapeutics Price Target Cut to $5.00/Share From $11.00 by BTIG
Oppenheimer Cuts Ovid to Perform, Cites Uncertainty Over Lead Drug
Express News | Citigroup Maintains Neutral on Ovid Therapeutics, Lowers Price Target to $1.2
Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
In the latest quarter, 6 analysts provided ratings for Ovid Therapeutics (NASDAQ:OVID), showcasing a mix of bullish and bearish perspectives.The table below provides a snapshot of their recent ratings
Institutional Owners May Take Dramatic Actions as Ovid Therapeutics Inc.'s (NASDAQ:OVID) Recent 75% Drop Adds to One-year Losses
Key Insights Institutions' substantial holdings in Ovid Therapeutics implies that they have significant influence over the company's share price A total of 8 investors have a majority stake in the c
loading...
No Data
Space Dust : other than these two fails, what else does Ovid have?
天天稳赚不赔 : Has this been shorted
Nidia_GirlOP Space Dust: they will try again to see what guidelines can be met for better results next time ..